ZVRA Quote, Financials, Valuation and Earnings

Akebia Therapeutics, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 0.92%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Akebia Therapeutics, Inc.'s return on equity of --.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 161.23%. On the other hand Akebia Therapeutics, Inc. has an analysts' consensus of $5.40 which suggests that it could grow by 255.26%. Given that Akebia Therapeutics, Inc. has higher upside potential than Zevra Therapeutics, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Zevra Therapeutics, Inc..

Zevra Therapeutics, Inc. has a beta of 1.080, which suggesting that the stock is 8.038% more volatile than S&P 500. In comparison Akebia Therapeutics, Inc. has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.559%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Akebia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are smaller than Akebia Therapeutics, Inc. quarterly revenues of $58.8M. Zevra Therapeutics, Inc.'s net income of -$544K is lower than Akebia Therapeutics, Inc.'s net income of $540K. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.68x while Akebia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 1.70x for Akebia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of -255.85%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 161.23%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -91.02%. Given that Zevra Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Zevra Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Zevra Therapeutics, Inc. has a beta of 1.080, which suggesting that the stock is 8.038% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Zevra Therapeutics, Inc.'s net income of -$544K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.68x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 15.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 18.38x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of -876.34%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Verastem, Inc.'s return on equity of -1773.4%.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 161.23%. On the other hand Verastem, Inc. has an analysts' consensus of $16.13 which suggests that it could grow by 104.89%. Given that Zevra Therapeutics, Inc. has higher upside potential than Verastem, Inc., analysts believe Zevra Therapeutics, Inc. is more attractive than Verastem, Inc..

Zevra Therapeutics, Inc. has a beta of 1.080, which suggesting that the stock is 8.038% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.157%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. Zevra Therapeutics, Inc.'s net income of -$544K is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.68x while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 36.78x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 52.48%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Zevra Therapeutics, Inc. has a consensus price target of $22.54, signalling upside risk potential of 161.23%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 115.58%. Given that Zevra Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Zevra Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

Zevra Therapeutics, Inc. has a beta of 1.080, which suggesting that the stock is 8.038% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.101%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Zevra Therapeutics, Inc.'s net income of -$544K is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.68x while XOMA Royalty Corp.'s PE ratio is 40.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.59x versus 10.41x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.